India’s Medtronic Private Limited has launched the Symplicity™ Spyral renal denervation system (RDN) for treating high blood pressure. RDN, a minimally invasive therapy targeting overactive kidney nerves, has been approved by the FDA and Indian regulatory authorities after ten years of clinical research and development, marking a significant milestone in the treatment of kidney-related hypertension.
The Symplicity SpyralTM blood pressure procedure is a minimally invasive procedure that reduces high blood pressure by targeting nerves near the kidneys that can become overactive. After sedation, a thin catheter is inserted into the kidney artery, which calms the nerves connected to the kidney. The tube is removed without leaving any implant behind.
This procedure can lower serious health risks. India’s hypertension, a major contributor to cardiovascular death, affects 1 in 4 adults and increases the risk of heart attack, stroke, heart failure, and kidney failure. Despite its prevalence, it often goes undiagnosed. Michael Blackwell, Vice President and Managing Director, Medtronic India said, “We are excited to offer this therapy to all eligible patients in India. As leaders in cardiovascular therapies, Medtronic remains committed to providing innovative solutions that improve patients’ lives.”